علاج ارتفاع ضغط الدم الرئوي الثانوي لأمراض الرئة في مرض الرئة الخلالي

References

DOI: 10.1093/eurheartj/ehac237

• Inhaled treprostinil may be considered in patients with PH associated with ILD.
• A phase 3 RCT (INCREASE) examined inhaled treprostinil at a target dose of 72 µg given four times daily in 326 patients with PH associated with ILD.
• In patients with ILD and PH, inhaled treprostinil may be considered based on the findings from the INCREASE study, but further data are needed, especially on long-term outcomes.
• The use of ambrisentan is not recommended in patients with PH associated with IPF.
• The use of riociguat is not recommended in patients with PH associated with IIP.
• At week 16, the placebo-corrected 6MWD improved by 31 m with inhaled treprostinil.
• There were also improvements in NT-proBNP and clinical worsening events, the latter driven by a lower proportion of patients whose 6MWD declined by >15% from baseline.